Leukemia Research
Volume 34, Issue 4 , Pages 454-457 , April 2010

Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2′-deoxyadenosine (2-CdA) and Rituximab

  • C. Rabascio

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 02 57489535; fax: +39 02 57489537.
    • ,
  • D. Laszlo

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
    • ,
  • G. Andreola

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
    • ,
  • L. Saronni

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
    • ,
  • D. Radice

      Affiliations

    • Dept of Epidemiology and Biostatistic, European Institute of Oncology, Milano, Italy
    • ,
  • L. Rigacci

      Affiliations

    • Dept of Haematology, University of Florence, Firenze, Italy
    • ,
  • A. Fabbri

      Affiliations

    • Dept of Haematology, University of Siena, Siena, Italy
    • ,
  • F. Frigeri

      Affiliations

    • Dept of Haematology, Istituto Nazionale dei Tumori, Napoli, Italy
    • ,
  • L. Calabrese

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
    • ,
  • A. Billio

      Affiliations

    • Central Hospital, Bolzano, Italy
    • ,
  • F. Bertolini

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy
    • ,
  • G. Martinelli

      Affiliations

    • Dept of Haematology, European Institute of Oncology, via Ripamonti 435, 20141 Milano, Italy

Received 21 April 2009 ,Revised 25 June 2009 ,Accepted 2 July 2009.

References 

  1. Pangalis GA, Nathwani BN, Rappaport H. Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenström. Cancer. 1977;39:999–1010
  2. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18:214–226
  3. Johnson SA, Birchall J, Luckie C, Oscier DG, Owen RG Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Guidelines on the management of Waldenström macroglobulinaemia. Br J Haematol. 2006;132:683–697
  4. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinemia. Blood. 2006;107:3442–3446
  5. Treon SP, Emmanouilides C, Kimby E, et al. Waldenström's Macroglobulinemia Clinical Trials Group Extended rituximab therapy in Waldenström's macroglobulinemia. Ann Oncol. 2005;16:132–138
  6. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol. 2003;30(2):243–247
  7. Zhu C, Johansson M, Permert J, Karlsson A. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguano sinekinase in cancer cell lines. J Biol Chem. 1998;273:14707–14711
  8. Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma. 2003;44:1705–1712[Review]
  9. Wright AM, Paterson AR, Sowa B, Akabutu JJ, Grundy PE, Gati WP. Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. Br J Haematol. 2002;116:528–537
  10. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 1993;81:597–601
  11. Cardoen S, Van den Neste E, Smal C, Rosier JF, Ferrant A, Van den Berghe G, et al. Effects of 2-chloro-2′-deoxyadenosine on the cell cycle in the human leukemia EHEB cell line. Nucleosides Nucleotides Nucleic Acids. 2004;23:1425–1429
  12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586
  13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–408
  14. Damaraju VL, Damaraju S, Young JD, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22:7524–7536
  15. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun. 2001;280(3):951–959
  16. Valdes R, Casado FJ, Pastor-Anglada M. Cell-cycle-dependent regulation of CNT1, a concentrative nucleoside transporter involved in the uptake of cell-cycle-dependent nucleoside-derived anticancer drugs. Biochem Biophys Res Commun. 2002;296(3):575–579
  17. Dragan Y, Valdes R, Gomez-Angelats M, Felipe A, Javier Casado F, Pitot H, et al. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology. 2000;32(2):239–246
  18. Farré X, Guillén-Gómez E, Sánchez L, Hardisson D, Plaza Y, Lloberas J, et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer. 2004;112(6):959–966

PII: S0145-2126(09)00349-X

doi: 10.1016/j.leukres.2009.07.002

Leukemia Research
Volume 34, Issue 4 , Pages 454-457 , April 2010

Article Tools

* Image Usage & Resolution